Soleno Therapeutics Inc (SLNO) Return on Equity ROE from the first quarter 2026 to first quarter 2025 and annually, average high and low, overall ranking from Mar 31 2026 to Mar 31 2025 - CSIMarket
Return on Equity, Quarterly Results, Trends, Rankings, Statistics
What is ROE for Soleno Therapeutics Inc in the first quarter 2026? Soleno Therapeutics Inc achieved a return on average equity (ROE) of 22.85 % in its first quarter 2026 a new company high.
While the company's net income was fading, Soleno Therapeutics Inc was able to improve its ROE compared to the fourth quarter 2025.
Within the Medical Equipment & Supplies industry 11 other companies had a higher return on equity. While Return on equity, overall ranking has advanced in the quarter, so far to 587, from total ROE ranking in the fourth quarter 2025 at 1362.
Soleno Therapeutics Public Offering Raises Questions Amidst Financial Struggles Soleno Therapeutics, a leading clinical-stage biopharmaceutical company focused on rare disease therapeutics, has recently undergone significant changes in its leadership and financial landscape. The resignation of Ernest Mario, Ph.D., as the Chair of the Board of Directors due to health reasons, and the appointment of Matthew Pauls, J.D., M.B.A., as the new Lead Independent Director, has sparked curiosity among investors and industry insiders. These developments coincide with Soleno Therapeutics recent announcement of its underwritten public offering, which aims to bolster the company s financial position. However, the timing of these changes and the public offering raises questions about Soleno Therapeutics overall stability and potential for success. The firm has recorded a staggering cumulative net loss of $-33 million during the 12 months ending in the third quarter of 2023. This alarming figure has resulted in a negative return on equity (ROE) of -272.88%, fueling concerns about the company s ability to generate profits and sustain shareholders confidence.
Soleno Therapeutics Submits New Drug Application for DCCR Tablets to Treat Prader-Willi Syndrome The pharmaceutical industry is constantly striving to develop innovative treatments for rare diseases, and Soleno Therapeutics is one company at the forefront of this mission. Soleno Therapeutics, a clinical-stage biopharmaceutical company, recently announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the approval of DCCR (diazoxide choline) extended-release tablets. This novel treatment is intended specifically for individuals aged four years and older who suffer from Prader-Willi syndrome (PWS) and experience hyperphagia, a condition that causes excessive hunger and uncontrolled eating. Prader-Willi syndrome is a complex genetic disorder that affects one in every 15,000 births worldwide. People with PWS face numerous physical, intellectual, and behavioral challenges that require proper management. Currently, there are limited treatment options available, making Soleno Therapeutics submission of the NDA a significant milestone in addressing this unmet medical need.
Soleno Therapeutics, a clinical-stage biopharmaceutical company specializing in developing innovative therapeutics for rare diseases, has recently made significant appointments to its leadership team. These strategic additions, along with the engagement of esteemed advisors, reflect the company s commitment to enhancing its commercial operations, expanding into European markets, and optimizing its human resources. With these new developments, Soleno Therapeutics aims to propel its growth trajectory and deliver novel treatments to patients in need. Appointments to the Leadership Team: Soleno Therapeutics has appointed Meredith Manning, M.B.A., as its Chief Commercial Officer, leveraging her extensive industry experience and expertise to drive commercial success. Manning s strategic guidance and leadership will be instrumental in advancing Soleno s pipeline and maximizing market potential. Additionally, Dairine Dempsey, Ph.D., has been appointed as the Vice President for Europe, charting the company s expansion into European markets. Lauren Budesheim, M.S., has also joined Soleno as the Vice President of Human Resources, responsible for nurturing a talented and driven workforce to support the company s growth aspirations.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
